Clinical Study to Investigate the Effectiveness of the TOPAS System to Treat Fecal Incontinence

Fecal Incontinence Clinical Trial

— TRANSFORM  

Official title:

An Investigation of the Treatment of Fecal Incontinence Using the TOPAS Sling System For Women (TRANSFORM)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01090739
• Other study ID #: WC0807
• Status: Completed
• Phase: N/A
• First received: March 19, 2010
• Last updated: August 25, 2016
• Start date: April 2010
• Est. completion date: April 2016

Study information

• Verified date: August 2016
• Source: ASTORA Women's Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate that the TOPAS System effectively treats fecal incontinence in women as measured by a 50% reduction in the number of FI episodes in a 14 day bowel diary at 12 months.

Description:

This is a prospective, multi-center, single-arm, open-label, two- stage, adaptive study conducted to obtain data to demonstrate the safety and effectiveness of the TOPAS system for the treatment of FI in women who have failed conservative therapy. It was approved by the FDA for up to 152 implanted subjects at up to 15 investigational sites in the US. Eight study centers are led by a Colorectal Surgeon and seven centers are led by an Urogynecologist.

This study is being conducted in compliance with Title 21 CFR Parts 11, 50, 54, 56, and 812; the principles of GCP as set forth in the World Medical Association Declaration of Helsinki (2008); and the ISO standard 14155:2011 (Clinical investigation of medical devices for human subjects - Good clinical practice).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 207
• Est. completion date: April 2016
• Est. primary completion date: November 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subject is/has:

1. An adult (>/= 18 years) female.

2. FI symptoms for a minimum of 6 months.

3. Failed two modalities of conservative therapies such as Dietary Modification, Pharmacologic Intervention, or Pelvic Floor Muscle Training.

4. <50 years old OR if >/= 50 years old, has had a negative cancer screening examination of the colon according screening guidelines (colonoscopy or barium enema + flexible sigmoidoscopy) within the past 3 years prior to informed consent date. (Note: if not done, the investigating physician must provide written justification for not having this exam and must be following the American Cancer Society Guidelines).

5. FI episodes = 4 in 14 day period.

Exclusion Criteria:

Subject is/has

1. Unable or unwilling to sign Informed Consent Form or comply with study requirements.

2. Currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study as determined by AMS.

3. Allergic to polypropylene.

4. Pregnant or planning a future pregnancy.

5. Less than 12 months (365 days) postpartum.

6. Pelvic prolapse >/=1 cm beyond the hymen (Stage III & IV)

7. Had stress urinary incontinence (SUI) or anterior repair within 3 months (90 days) prior to TOPAS Sling System implantation.

8. Had a hysterectomy, Sphincteroplasty, or Posterior surgery within 6 months (180 days) prior to TOPAS Sling System implantation.

9. Had rectal surgery (such as rectopexy) within 12 months (365 days) of TOPAS Sling System implantation.

10. Planning pelvic surgery within 12 months (365 days) post implant

11. Current Grade III or IV hemorrhoids.

12. Neurological or psychological condition as cause of FI such as MS, dementia, brain tumor.

13. Diagnosed Inflammatory Bowel Disease (for example, ulcerative colitis or Crohn's disease).

14. Chronic, watery diarrhea, unmanageable by drugs or diet, as primary cause of fecal incontinence.

15. Severe chronic constipation, including obstructive defecatory disorder.

16. External full thickness rectal prolapse.

17. A history of laxative abuse within the past 5 years.

18. Had previous rectal resection.

19. Active pelvic infection, perianal or recto-vaginal fistula.

20. Congenital anorectal malformations or chronic 4th degree lacerations and cloacae.

21. History of therapeutic radiation for cancers of the pelvis.

22. Currently implanted with a sacral nerve stimulator.

23. Contraindicated for surgery or having any condition that would compromise wound healing.

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fecal Incontinence

Intervention

Device:
• TOPAS Treatment for Fecal Incontinence
The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.

Locations

Country	Name	City	State
United States	St. Luke's Hospital	Allentown	Pennsylvania
United States	University of Michigan	Ann Arbor	Michigan
United States	University of North Carolina - Chapel Hill	Chapel Hill	North Carolina
United States	The Christ Hospital	Cincinnati	Ohio
United States	Cleveland Clinic Foundation - Ohio	Cleveland	Ohio
United States	Womens Hospital of Texas	Houston	Texas
United States	Abbott Northwestern Hospital	Minneapolis	Minnesota
United States	Atlantic Health System	Morristown	New Jersey
United States	University of Oklahoma	Oklahoma City	Oklahoma
United States	University of California SF - Mt Zion Medical Center	San Francisco	California
United States	Sacred Heart Medical Center	Spokane	Washington
United States	University of South Florida	Tampa	Florida
United States	Raybon OB-GYN	Toccoa	Georgia
United States	Cleveland Clinic Foundation - Florida	Weston	Florida

Sponsors (1)

Lead Sponsor	Collaborator
ASTORA Women's Health

Country where clinical trial is conducted

United States, 

References & Publications (1)

Mellgren A, Zutshi M, Lucente VR, Culligan P, Fenner DE; TOPAS Study Group. A posterior anal sling for fecal incontinence: results of a 152-patient prospective multicenter study. Am J Obstet Gynecol. 2016 Mar;214(3):349.e1-8. doi: 10.1016/j.ajog.2015.10.0 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in the Haff Surgical Satisfaction Questionnaire (SSQ-8)	The SSQ-8 is an 8 item questionnaire to assess subject surgical satisfaction as described by Murphy M, Sternschuss G, Haff R, van Raalte H, Saltz S, Lucente V. Quality of life and surgical satisfaction after vaginal reconstructive vs. obliterative surgery for the treatment of advanced pelvic organ prolapse. Am J Obstet Gynecol. 2008 May;198(5):573.e1-7. The SSQ-8 was collected as an optional one-time assessment from implanted subjects between the 3 and 36 month visits. Scale is scored on 0-100 with higher scores are better	36 Month Follow-up Visit	No
Other	Change in Health Resource Usage: # Pads Per Day Subject Took for FI	Change in health resource usage using sponsor-created questionnaire: # days in hospital due to FI	36 Month Follow-up Visit	No
Other	Change in Health Resource Usage: # Days in Hospital, Took Off Work, or Others Took Off Work Due to FI	Change in health resource usage using sponsor-created questionnaire	36 Month Follow-up Visit	No
Other	Change in Health Resource Usage: # Physician Visits Due to FI	Change in health resource usage using sponsor-created questionnaire	36 Month Follow-up Visit	No
Primary	Percentage of Responders	The primary endpoint for efficacy is the 14 day bowel diary documenting liquid or solid fecal incontinence episodes. A 50% reduction in the number of FI episodes is considered a treatment responder.	12 Months	No
Secondary	Change in Fecal Incontinence Episodes	Number of fecal incontinence episodes in a 14 day period	36 Month Follow-up Visit	No
Secondary	Change in Fecal Incontinence Days	Number of fecal incontinence days in a 14 day period	36 Month Follow-up Visit	No
Secondary	Change in Urge Fecal Incontinence Episodes	Number of urge fecal incontinence episodes in a 14 day period	36 Month Follow-up Visit	No
Secondary	Change in Wexner Symptom Severity Score	Wexner Symptom Severity Score for fecal incontinence (also known as the Cleveland Clinic Incontinence Score) as described by Jorge and Wexner, 1993 (Jorge JM, Wexner SD. Etiology and management of fecal incontinence. Dis Colon Rectum. 1993 Jan;36(1):77-97). Measured on a 0-20 scale with lower scores equal to less fecal incontinence.	36 Month Follow-up Visit	No
Secondary	Change in Fecal Incontinence Quality of Life Score	Fecal Incontinence Quality of Life Score as described by Rockwood et al., 2000 (Rockwood TH, Church JM, Fleshman JW, Kane RL, Mavrantonis C, Thorson AG, Wexner SD, Bliss D, Lowry AC. Fecal Incontinence Quality of Life Scale: quality of life instrument for patients with fecal incontinence. Dis Colon Rectum. 2000 Jan;43(1):9-16; discussion 16-7). Four domains of lifestyle, coping, depression, and embarrassment. Measured on a 0-4 scale with higher scores equal to better quality of life.	36 Month Follow-up Visit	No
Secondary	Change in Pelvic Floor Distress Inventory (PFDI-20) Scores	Short-form version of the Pelvic Floor Distress Inventory (PFDI-20) as described by Barber et al., 2005 (Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7. Am J Obstet Gynecol. 2005 Jul;193(1):103-13).; The short-form version of the Pelvic Floor Distress Inventory has a total of 20 questions and 3 scales (Urinary Distress Inventory, Pelvic Organ Prolapse Distress Inventory, and Colorectal-Anal Distress Inventory). Total PFDI score measured on a 0-300 scale with higher scores equal to greater pelvic floor distress. As with the Total PFDI Score, higher subscale scores equal greater pelvic floor distress, on a 0-100 scale.	36 Month Follow-up Visit	No
Secondary	Change in Pelvic Floor Impact Questionnaire (PFIQ-7) Scores	Short-form version of the Pelvic Floor Impact Questionnaire (PFIQ-7) as described by Barber et al., 2005 (Barber MD, Walters MD, Bump RC. Short forms of two condition-specific quality-of-life questionnaires for women with pelvic floor disorders (PFDI-20 and PFIQ-7. Am J Obstet Gynecol. 2005 Jul;193(1):103-13).; The short-form version of the Pelvic Floor Impact Questionnaire has a total of 7 questions and 3 scales (Urinary Impact, Pelvic Organ Prolapse Impact, and Colorectal-Anal Impact). Total PFIQ score measured on a 0-300 scale with higher scores equal to greater pelvic floor impact. Subscales scored on 0-100 scale and the higher the score the greater pelvic floor impact, exactly like the Total PFIQ score.	36 Month Follow-up Visit	No
Secondary	Change in Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12)	Pelvic Organ Prolapse/Urinary Incontinence Sexual Function Questionnaire (PISQ-12) as described by Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12). Int Urogynecol J Pelvic Floor Dysfunct. 2003 Aug;14(3):164-8; discussion 168. Measured on a 0-48 scale with higher scores equal to better sexual function.	36 Month Follow-up Visit	No
Secondary	Change in Numeric Pelvic Pain Scale (NPPS)	Numeric Pelvic Pain Scale (NPPS) adapted from McCafferty M, Pasero C. Pain: Clinical Manual. 2nd ed. Philadelphia: Mosby Inc.; 1999. Chapter 3, Assessment Tools; p. 58-75. The NPPS is scored on a 0-10 scale with higher scores indicating more severe pain. Since the NPPS was introduced later in the study, earlier implanted subjects did not have the baseline NPPS score and a change from baseline could not be calculated.	12 Month Follow-up Visit	Yes

External Links

•   Primary (1 Year) Results Manuscript